Masimo Pronto-7® Wins GOLD “Stevie®” Award for Best New Health Product
IRVINE, Calif., Sept. 20, 2012 /PRNewswire/ — Masimo Corporation (NASDAQ: MASI) announced today that its Pronto-7(®) handheld noninvasive hemoglobin, arterial oxygen saturation (SpO2), pulse rate, and perfusion index spot-check testing device earned a 2012 GOLD Stevie(®) American Business Award for the Best New Product or Service in the Health & Pharmaceuticals category.
This marks the fourth industry award the innovative Pronto-7 has won since its commercialization last year. The 2012 Stevie Award winners were honored recently at a presentation ceremony at the Julia Morgan Ballroom, Merchants Exchange in San Francisco.
The Pronto-7 is a palm-sized device designed for quick-and-easy noninvasive total hemoglobin (SpHb(®)) spot-check testing, along with SpO2, pulse rate, and perfusion index. Extremely lightweight at approximately 296g, the Pronto-7 delivers total hemoglobin measurement results–a physiological parameter that previously required an invasive blood draw and time-consuming lab analysis–in under one minute. Offering needle-less and pain-free hemoglobin testing, the Pronto-7 is a cost-effective solution for immediate, on-the-spot hemoglobin testing that is raising the expectations of patients and clinicians alike to more advanced healthcare at the earliest moment of care.
“We are honored the Pronto-7 has earned a GOLD Stevie award, emerging atop an extremely competitive field this year,” said Joe Kiani, Founder and CEO of Masimo. “The Pronto-7 incorporates some of Masimo’s most advanced technology to help overcome many of the challenges and risks associated with invasive hemoglobin sampling for both clinicians and patients – enabling fast, accurate, painless, needle-free total hemoglobin measurements.”
The Stevie Awards were created to honor and generate public recognition of the achievements and positive contributions of organizations and business people worldwide. Beginning with The American Business Awards in 2002, The International Business Awards in 2003, The Stevie Awards for Women in Business in 2004, and the Stevie Awards for Sales & Customer Service in 2006, the program’s mission is to raise the profile of exemplary organizations and individuals among the press, the business community, and the general public. The Stevie has become one of the world’s most coveted awards.
The American Business Awards are judged each year by more than 200 executives nationwide. Sponsors include several of the top business publishers and marketers.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care–helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET(®), which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET(®) outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET(®) Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb(®)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(®)), methemoglobin (SpMet(®)), and Pleth Variability Index (PVI(®)), in addition to SpO(2), pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet(TM), a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow(®) Acoustic Monitoring((TM)), the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa(TM)). Masimo’s rainbow(®) SET(®) technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine(®), a pioneer in the development of innovative brain function monitoring technology and devices. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and acquired PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET(®) and Masimo rainbow(®) SET(®) technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications(®).” Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using the new Masimo Pronto-7 and noninvasive sensor sizes, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO(2), pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC“), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Phone: (949) 297-7434
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.
SOURCE Masimo Corporation